Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prasugrel
Drug ID BADD_D01822
Description Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
Indications and Usage Indicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI). May be used in patients with unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) who are to be managed with PCI. Prasugrel is not recommended in patients 75 years of age or greater, those that weigh<60kg, and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding.
Marketing Status Prescription
ATC Code B01AC22
DrugBank ID DB06209
KEGG ID D05597
MeSH ID D000068799
PubChem ID 6918456
TTD Drug ID D07IRF
NDC Product Code 65162-001; 51407-444; 51407-445; 0378-5185; 60505-4642; 65162-002; 14501-0084; 0378-5186; 67877-605; 51407-247; 50090-5169; 43817-240; 60505-4643; 65862-829; 67877-604; 16729-272; 16729-273; 65862-830; 51407-248; 50090-4118; 43817-239; 66003-602; 66003-601
Synonyms Prasugrel Hydrochloride | Hydrochloride, Prasugrel | Prasugrel HCl | HCl, Prasugrel | CS 747 | 747, CS | CS-747 | CS747 | Prasugrel | Efient | Effient | LY 640315 | 640315, LY | LY640315 | LY-640315
Chemical Information
Molecular Formula C20H20FNO3S
CAS Registry Number 150322-43-3
SMILES CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cough22.02.03.0010.003523%
Death08.04.01.001--
Depressed level of consciousness17.02.04.0020.000460%
Dermatitis23.03.04.002--Not Available
Dermatomyositis23.03.02.001; 15.05.01.002; 10.04.02.0010.001762%Not Available
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.007047%
Drug hypersensitivity10.01.01.001--Not Available
Dysphagia07.01.06.0030.001762%
Dyspnoea02.01.03.002; 22.02.01.004--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Embolic stroke24.01.04.010; 17.08.01.0320.001762%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.007047%
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Eye haemorrhage06.07.02.001; 24.07.05.002--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.002643%Not Available
Gastric haemorrhage24.07.02.007; 07.12.01.0010.002643%
Gastric polyps16.05.03.001; 07.20.01.0030.001762%Not Available
Gastritis erosive07.04.03.0030.001762%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.010570%Not Available
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Haematemesis07.12.02.002; 24.07.02.0110.001762%Not Available
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haematocrit decreased13.01.05.0010.002643%Not Available
Haematoma24.07.01.0010.002643%
Haematuria24.07.01.047; 20.02.01.0060.003523%
Haemoglobin13.01.05.018--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages